GUD Fundamental Analysis - KNIGHT THERAPEUTICS INC

Fundamental Rating

Taking everything into account, GUD scores 4 out of 10 in our fundamental rating. GUD was compared to 32 industry peers in the Pharmaceuticals industry. GUD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GUD shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GUD has reported negative net income.

GUD had a positive operating cash flow in the past year.

In multiple years GUD reported negative net income over the last 5 years.

Of the past 5 years GUD 4 years had a positive operating cash flow.

1.2 Ratios

GUD has a Return On Assets of 0.04%. This is in the better half of the industry: GUD outperforms 62.50% of its industry peers.

The Return On Equity of GUD (0.05%) is better than 65.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	0.04%
ROE	0.05%
ROIC	N/A

ROA(3y)-1.39%

ROA(5y)0.29%

ROE(3y)-1.78%

ROE(5y)0.26%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GUD has a Profit Margin of 0.10%. This is in the better half of the industry: GUD outperforms 62.50% of its industry peers.

GUD's Profit Margin has declined in the last couple of years.

Looking at the Gross Margin, with a value of 42.92%, GUD is in line with its industry, outperforming 59.38% of the companies in the same industry.

In the last couple of years the Gross Margin of GUD has declined.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	0.1%
GM	42.92%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y-43.41%

PM growth 5Y-47.95%

GM growth 3Y-0.3%

GM growth 5Y-3.67%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.

GUD has less shares outstanding than it did 1 year ago.

GUD has less shares outstanding than it did 5 years ago.

Compared to 1 year ago, GUD has an improved debt to assets ratio.

2.2 Solvency

GUD has an Altman-Z score of 2.06. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 2.06, GUD belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.

A Debt/Equity ratio of 0.11 indicates that GUD is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.11, GUD is in the better half of the industry, outperforming 65.63% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	N/A
Altman-Z	2.06

ROIC/WACCN/A

WACC8.42%

2.3 Liquidity

A Current Ratio of 2.47 indicates that GUD has no problem at all paying its short term obligations.

With a decent Current ratio value of 2.47, GUD is doing good in the industry, outperforming 65.63% of the companies in the same industry.

GUD has a Quick Ratio of 1.50. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of GUD (1.50) is better than 65.63% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.47
Quick Ratio	1.5

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 100.00% over the past year.

GUD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.46% yearly.

GUD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.82%.

The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)100%

EPS 3Y-25.31%

EPS 5Y-13.46%

EPS Q2Q%-550%

Revenue 1Y (TTM)13.82%

Revenue growth 3Y15.1%

Revenue growth 5Y50.87%

Sales Q2Q%12.33%

3.2 Future

The Earnings Per Share is expected to grow by 53.83% on average over the next years. This is a very strong growth

Based on estimates for the next years, GUD will show a quite strong growth in Revenue. The Revenue will grow by 9.95% on average per year.

EPS Next Y-330.28%

EPS Next 2Y10.09%

EPS Next 3Y50.87%

EPS Next 5Y53.83%

Revenue Next Year14.81%

Revenue Next 2Y12.31%

Revenue Next 3Y8.59%

Revenue Next 5Y9.95%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Forward Earnings ratio of 95.38 indicates a quite expensive valuation of GUD.

68.75% of the companies in the same industry are more expensive than GUD, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 22.85. GUD is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	95.38

4.2 Price Multiples

GUD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. GUD is cheaper than 65.63% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	12.66

4.3 Compensation for Growth

A more expensive valuation may be justified as GUD's earnings are expected to grow with 50.87% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.09%

EPS Next 3Y50.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GUD does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KNIGHT THERAPEUTICS INC

TSX:GUD (10/16/2025, 7:00:00 PM)

5.78

+0.03 (+0.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)11-06 2025-11-06

Inst Owners14.23%

Inst Owner ChangeN/A

Ins Owners1.86%

Ins Owner ChangeN/A

Market Cap575.98M

Analysts78.18

Price Target7.96 (37.72%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-224.57%

Min EPS beat(2)-815.07%

Max EPS beat(2)365.93%

EPS beat(4)2

Avg EPS beat(4)-21.94%

Min EPS beat(4)-815.07%

Max EPS beat(4)461.4%

EPS beat(8)3

Avg EPS beat(8)-230%

EPS beat(12)6

Avg EPS beat(12)-123.05%

EPS beat(16)7

Avg EPS beat(16)-384.28%

Revenue beat(2)2

Avg Revenue beat(2)5.97%

Min Revenue beat(2)0.88%

Max Revenue beat(2)11.06%

Revenue beat(4)4

Avg Revenue beat(4)5.89%

Min Revenue beat(4)0.88%

Max Revenue beat(4)11.06%

Revenue beat(8)7

Avg Revenue beat(8)5%

Revenue beat(12)11

Avg Revenue beat(12)8.91%

Revenue beat(16)14

Avg Revenue beat(16)9.42%

PT rev (1m)0%

PT rev (3m)3.12%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-110.42%

EPS NY rev (1m)0%

EPS NY rev (3m)-302.85%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-0.5%

Revenue NY rev (1m)0%

Revenue NY rev (3m)4.47%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	95.38
P/S	1.5
P/FCF	N/A
P/OCF	18.94
P/B	0.75
P/tB	2
EV/EBITDA	12.66

EPS(TTM)0

EYN/A

EPS(NY)0.06

Fwd EY1.05%

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)0.31

OCFY5.28%

SpS3.86

BVpS7.66

TBVpS2.89

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	0.04%
ROE	0.05%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	0.1%
GM	42.92%
FCFM	N/A

ROA(3y)-1.39%

ROA(5y)0.29%

ROE(3y)-1.78%

ROE(5y)0.26%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y-43.41%

PM growth 5Y-47.95%

GM growth 3Y-0.3%

GM growth 5Y-3.67%

F-Score6

Asset Turnover0.37

Health

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	N/A
Debt/EBITDA	1.96
Cap/Depr	62.43%
Cap/Sales	8.29%
Interest Coverage	N/A
Cash Conversion	72.19%
Profit Quality	N/A
Current Ratio	2.47
Quick Ratio	1.5
Altman-Z	2.06

F-Score6

WACC8.42%

ROIC/WACCN/A

Cap/Depr(3y)40.08%

Cap/Depr(5y)130.51%

Cap/Sales(3y)6.77%

Cap/Sales(5y)24.55%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)100%

EPS 3Y-25.31%

EPS 5Y-13.46%

EPS Q2Q%-550%

EPS Next Y-330.28%

EPS Next 2Y10.09%

EPS Next 3Y50.87%

EPS Next 5Y53.83%

Revenue 1Y (TTM)13.82%

Revenue growth 3Y15.1%

Revenue growth 5Y50.87%

Sales Q2Q%12.33%

Revenue Next Year14.81%

Revenue Next 2Y12.31%

Revenue Next 3Y8.59%

Revenue Next 5Y9.95%

EBIT growth 1Y-652.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year397.68%

EBIT Next 3Y80.27%

EBIT Next 5Y53.84%

FCF growth 1Y-140.33%

FCF growth 3YN/A

FCF growth 5Y23.85%

OCF growth 1Y60.79%

OCF growth 3Y-6.66%

OCF growth 5Y51.14%

KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens